Table 1.
Characteristics of 678 Participants Initiating ART*
| HIV/TB (n = 135) | HIV Only (n = 543) | P Valuea | |
|---|---|---|---|
| Male sex, n (%) | 74 (54.8) | 209 (38.5) | <.01 |
| Age, years | 34 (28–42) | 32 (28–40) | .25 |
| BMI, kg/m2 | 19 (17–20) | 19 (18–21) | <.01 |
| MUAC, cm | 21.5 (20.0–23.0) | 23.0 (21.0–25.0) | <.01 |
| Karnofsky performance score, n (%) | .14 | ||
| <70 | 6 (4.5) | 24 (4.5) | |
| 70 or 80 | 72 (54.5) | 242 (45.2) | |
| 90 or 100 | 54 (40.9) | 269 (50.3) | |
| On co-trimoxazole at study inclusion, n (%) | 98 (73.1) | 420 (77.6) | .27 |
| Newly enrolled in HIV care, n (%) | 51 (37.8) | 166 (30.7) | .12 |
| CD4 cell count, cells/µLb | 161 (98–243) | 184 (118–256) | .05 |
| CD4 cell strata, n (%), cells/µL | .11 | ||
| <100 | 34 (25.8) | 103 (19.3) | |
| 100–200 | 53 (40.2) | 203 (37.9) | |
| 201–350 | 31 (23.5) | 180 (33.6) | |
| >350 | 14 (10.6) | 49 (9.2) | |
| CD4 cell percentage, % | 11.0 (7.8–15.0) | 11.0 (7.0–15.0) | .91 |
| Hemoglobin, g/dLc | 10.4 (9.2–12.0) | 11.6 (10.5–12.7) | <.01 |
| White blood cell count, ×109 cells/L | 4.7 (3.7–6.2) | 4.2 (3.4–5.4) | <.01 |
| Total lymphocyte count, ×109 cells/L | 1.3 (1.0–1.8) | 1.4 (1.1–1.8) | .30 |
| ART regimen – n (%)d | <.01 | ||
| Nevirapine-based | 10 (7.4) | 113 (20.8) | |
| Efavirenz-based | 125 (92.6) | 430 (79.2) |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; MUAC, mid-upper arm circumference; TB, tuberculosis.
* Variables presented as median (IQR), if not stated otherwise. P values of < .05 have been indicated in bold.
a The P values were calculated using Mann-Whitney U or χ2 test, as appropriate.
b CD4 cell counts were available for 667 patients.
c Blood cell counts were available for 639 patients.
d Nucleoside/nucleotide components: lamivudine 100%; stavudine 2%; zidovudine 12%; tenofovir 86%.